Chromomycosis. Treatment with thiabendazole

Bayles, Margaret A. H.

doi:10.1001/archderm.104.5.476

Cited by 32 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The length of drug administration mu.st be guided by the application of clinical, mycologic, and histopathologic criteria. The severe cases in our trial satisfied the criteria of clinical healing or clinical improvement, but in these patients parasites were still present at the control biopsies, showing that sterilization of their lesions was not ob- 12 3 4 5 6 7 9 10 1112 13 14 15 Patient No. taincd.…”

Section: Discussionmentioning

confidence: 99%

ITRACONAZOLE IN THE TREAMENT OF CHROMOBLASTOMYCOSIS DUE TO FONSECAEA PEDROSOI

et al. 1992

View full text Add to dashboard Cite

The efficacy and tolerability of itraconazole in chromoblastomycosis due to Fonsecaea pedrosoi were evaluated in a non-comparative open clinical trial in 19 Brazilian patients with histopathologically and mycologically proven active chromoblastomycosis. Patients were classified in terms of severity and received itraconazole at the dosage of 200 to 400 mg per day until previously described criteria of cure have been reached. Clinical, mycologic, histopathologic, and laboratory evaluations were performed before, during, and after therapy. The plasma levels of itraconazole and the in vitro susceptibility of the isolates were determined in 15 cases. Clinical and biologic cure were achieved by eight patients (42%) having mild to moderate disease, after a mean duration of therapy of 7.2 months (3.2-29.6 months). Sterile scarred lesions were observed in a post-therapy follow-up lasting on average 9.6 months that was carried out in this subgroup. Clinical cure alone occurred after a mean period of 25.1 months of treatment (16-30.5 months) in seven patients (36%) with moderate to severe disease. Finally, clinical improvement was obtained in four patients (21%) with severe lesions after a mean treatment time of 17.6 months (10.7-22.5 months). All patients responded favorably to itraconazole therapy. No significant side effects nor biochemical alteration during this trial were important enough to interrupt the treatment. Our results support those of previous trials, suggesting that itraconazole is an effective compound against chromoblastomycosis due to Fonsecaea pedrosoi.

show abstract

Section: Discussionmentioning

confidence: 99%

ITRACONAZOLE IN THE TREAMENT OF CHROMOBLASTOMYCOSIS DUE TO FONSECAEA PEDROSOI

et al. 1992

View full text Add to dashboard Cite

show abstract

“…Thiabendazole, ketoconazole (KTZ), saperconazole (SPZ) and itraconazole (ITZ) have been tested and the latter seems to be the most adequate (Battistini & Sierra 1969, Bayles & Durban 1971, Drouhet et al 1982, Silber et al 1983, EspinelIngroff et al 1984, Restrepo et al 1988, Grant & Clissold 1989, Franco et al 1992. Small lesions have responded to treatments with ITZ administered for periods of 18 to 24 months, in doses of 100 to 200 mg/day.…”

mentioning

confidence: 99%

Chromoblastomycosis murine model and in vitro test to evaluate the sensitivity of Fonsecaea pedrosoi to ketoconazole, itraconazole and saperconazole

Cardona-Castro

Agudelo‐Flórez

Restrepo-Molina

1996

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…Treatment of chromomycosis is aimed at eradication through the use of a variety of antifungal medications. Systemic agents, such as 5‐fluorocytosine (5‐FU), 1 thiabendazole, 2 amphotericine B, 3 ketoconazole, 4 and miconazole 5 are used for chronic and extensive lesions. Recently, we also found reports on the use of newer antifungal drugs, such as itraconazole, 6 fluconazole, 7 and terbinafine 8 .…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of chromomycosis using carbon dioxide laser associated with topical heat applications

Hira

Yamada

Takahashi

et al. 2002

Acad Dermatol Venereol

View full text Add to dashboard Cite

A 59-year-old Japanese man presented with a slightly elevated, pruritic, erythematous plaque on his left buttock measuring 5 x 5 cm in diameter. The man had a history of chromomycosis, dating 6 years prior to the current consultation, for which he had been treated with oral terbinafine. Diagnosis of a recurrence of chromomycosis of the skin due to infection by Foncecaea pedrosoi was made after careful analysis of the clinical features, skin biopsy, KOH mounts, and fungal culture results. We administered topical heat therapy followed by treatment with CO2 laser to eradicate the unresponsive remnants of the lesion. The operative site re-epithelized within 10 weeks, and 1 year after the treatment there was no evidence of recurrence. For a recalcitrant case of chromomycosis, as in this case, the use of CO2 laser combined with topical heat therapy may be a new therapeutic modality.

show abstract

Chromomycosis. Treatment with thiabendazole

Cited by 32 publications

References 9 publications

ITRACONAZOLE IN THE TREAMENT OF CHROMOBLASTOMYCOSIS DUE TO FONSECAEA PEDROSOI

ITRACONAZOLE IN THE TREAMENT OF CHROMOBLASTOMYCOSIS DUE TO FONSECAEA PEDROSOI

Chromoblastomycosis murine model and in vitro test to evaluate the sensitivity of Fonsecaea pedrosoi to ketoconazole, itraconazole and saperconazole

Successful treatment of chromomycosis using carbon dioxide laser associated with topical heat applications

Contact Info

Product

Resources

About